CClinicalTrials.gg
CompletedNCT03358732Updated Dec 2, 2017

Effect of Intrauterine Navigation Using Intrauterine Insemination Catheter for Mock Embryo Transfer Prior to Day 3 Embryo Transfer on Pregnancy Rate: A Pilot Study

An interventional study of endometrial navigation one day before the embyo transfer using IUI catheter , in The Study Focusses on Improving the Implantation Rate in IVF, sponsored by King Fahad Medical City. Completed at 1 site in Saudi Arabia. Open to female participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by King Fahad Medical City · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

Objective: To evaluate the effect of intrauterine navigation using intrauterine insemination catheter (IUI) one day prior to day 3 embryo transfer (ET) on pregnancy rate.

Design: Pilot randomized controlled study. Setting: Tertiary referral center, King Fahad Medical City. Patients: Patients who underwent ET during the period of the study after two or less in-vitro fertilization failures and fulfilled the inclusion criteria.

Interventions: Mock ETs were performed on day 2 post oocytes retrieval using intrauterine insemination catheter, followed by day 3 ET.

Main Outcome Measure: Pregnancy rate.

Key Words: embryo transfer, mock embryo transfer, endometrial receptivity, endometrial scratching, IVF.

Read the detailed description

Materials and Methods Population Forty-five patients were selected for this prospective randomized control trial. It was conducted between October 2016 and October 2017 in the Reproductive Endocrinology and Infertility Medicine Department of King Fahad Medical City (KFMC).

We included nulliparous patients who were \< 42 years of age with body mass index (BMI) \< 30 kg/m2 and normal endometrial cavity, used fresh sperm or oocytes, had two or more embryos available for transfer on day 3 post ovum pick-up (OPU), and no more than 3 previous unsuccessful ART cycles. Patients with uterine fibroids, uterine anomalies, intra-uterine adhesions, and uterine polyps, patients with chronic diseases in the as uncontrolled diabetes or hypertension, or if the patient had difficult mock ET . patients with severe male factors for infertility requiring surgical retrieval of sperms were excluded from the study.

Ethical clearance of this study was obtained from the ethical committee of KFMC (IRB 00008644). Written informed consent was obtained from all the participants.

Stimulation Protocols Participants were assigned either to the antagonist or agonist protocol. In the agonist stimulation protocol, pituitary desensitization was achieved by using 3.75 mg leuprolide acetate (Lupron Depot, Abbott Laboratories, Chicago, USA) intramuscularly in the luteal phase of the previous cycle. The participants received 75-450 IU/d of either recombinant follicle-stimulating hormone (FSH) (Gonal-F; Serono, Munich, Germany) or highly purified human menopausal gonadotrophin (hMG) (Merional; IBSA, Lugno, Switzerland). The dosage was adjusted according to the serum E2 levels and vaginal ultrasound folliculometry. In the antagonist protocol group, 0.25 mg/d cetrorelix acetate (Cetrotide; Serono, Munich, Germany) was added on the day 5 of stimulation. When the sizes of three or more follicles became ≥16 mm, the patient was given 10,000 IU of chorionic gonadotrophin (Pregnyl; MERK, Hally, Germany) intramuscularly.

Oocyte Retrieval and Fertilization Transvaginal oocyte retrieval was scheduled 36 h after the administration of hCG and was performed under local anesthesia. Fertilization was achieved by intracytoplasmic sperm injection (ICSI). Pronuclear observation to determine fertilization was performed 16-18 h after insemination. A commercial sequential IVF medium (Cook, Eight Miles Plains, Queensland, Australia) was used for procedures involving the handling of gametes and embryos. All embryos were transferred on their respective day 3 post OPU.

Mock Embryo Transfer On day 2 post OPU, one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.

Embryo Transfer On the morning of ET, the patient was taken to the operating room with a moderately full bladder. To facilitate safe handling of the embryos, the operating room was connected to the embryology laboratory through a sliding door. The patient was placed in the lithotomy position and the embryos were loaded by the embryologist into the soft catheter. A maximum of two embryos were transferred per cycle. The physician then inserted the catheter into the uterus till it was approximately 1.5 cm from the fundus, and expelled the embryos. The catheter was then slowly removed from the uterus and returned to the embryologist for inspection for any remnant embryos (retained embryos for reloading), blood, or mucus.

Intravaginal progesterone (Cyclogest; 400 mg, Actavis, Devon, UK) was administered every 12 h for luteal support.

Quantitative assessment of serum ß-HCG level was performed two weeks after ET. Patients who showed high levels of serum ß-HCG were considered as pregnant and were asked to return at 6 weeks of gestation for ultrasonographic confirmation. When they returned, clinical pregnancy was determined by the observation of a gestational sac with fetal heart beat on transvaginal ultrasound. The clinical embryo implantation rate was defined as the number of gestational sacs observed at 6 weeks of gestation divided by the total number of embryos transferred.

Statistical Methods Statistical analyses were performed using SPSS (version 12.0; SPSS, Inc., Chicago, IL, USA). Results were tabulated and presented in percentages. Statistical analyses were carried out using the chi-squared test or the Fisher Exact test for categorical variables, and the unpaired two-way Student's t-test for continuous variables. A value of P ≤ 0.05 was accepted as statistically significant.

02

Conditions studied

  • The Study Focusses on Improving the Implantation Rate in IVF

Keywords

  • embryo transfer, mock embryo transfer, endometrial receptivity, endometrial scratching, IVF
03

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

We included nulliparous patients who were \< 42 years of age with body mass index (BMI) \< 30 kg/m2 and normal endometrial cavity, used fresh sperm or oocytes, had two or more embryos available for transfer on day 3 post ovum pick-up (OPU), and no more than 3 previous unsuccessful ART cycles

Exclusion criteria

Exclusion Criteria:

Patients with uterine fibroids, uterine anomalies, intra-uterine adhesions, and uterine polyps, patients with chronic diseases in the as uncontrolled diabetes or hypertension, or if the patient had difficult mock ET . patients with severe male factors for infertility requiring surgical retrieval of sperms were excluded from the study.

-

04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Mock embryo transfer

    The patients underwent a mock embryo transfer one day before the scheduled actual transfer

    Device: endometrial navigation one day before the embyo transfer using IUI catheter ,

  • No intervention
    No mock embryo transfer

    The patients did not undergo mock embryo transfer one day before the scheduled actual transfer

Interventions

  • Deviceendometrial navigation one day before the embyo transfer using IUI catheter ,

    one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.

05

What researchers measure

Primary outcomes

  1. Pregnancy rate

    Proportion of women with visualization of intrauterine gestation sac with positive fetal heart

    Time frame: 1 month

06

Study locations

1 site
  • king Fahad Medical City
    Riyadh, Central 11525, Saudi Arabia
07

Registry details

Key details

Study ID
NCT03358732
Lead sponsor
King Fahad Medical City
Responsible party
Sahar Abbas Lary (Consultant, King Fahad Medical City) — Principal investigator
First posted
Dec 2, 2017
Start date
Oct 2, 2016
Primary completion
Oct 3, 2017
Completion
Oct 3, 2017
Last update
Dec 2, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion